Infliximab originator and biosimilars have similar efficacy in children with inflammatory bowel disease
{{output}}
Objectives: To evaluate whether children with inflammatory bowel disease (IBD) who initiate infliximab originator versus biosimilar experience similar clinical outcomes at 12 months. ... ...
